<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    scd
   </journal-id>
   <journal-title-group>
    <journal-title>
     Stem Cell Discovery
    </journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2161-6760
   </issn>
   <issn publication-format="print">
    2161-6787
   </issn>
   <publisher>
    <publisher-name>
     Scientific Research Publishing
    </publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">
    10.4236/scd.2024.141001
   </article-id>
   <article-id pub-id-type="publisher-id">
    scd-138371
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Articles
     </subject>
    </subj-group>
    <subj-group subj-group-type="Discipline-v2">
     <subject>
      Biomedical 
     </subject>
     <subject>
       Life Sciences
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    Mesenchymal Stem Cell-Derived Secretome-Based Therapy for Neurological Disorders: A Scoping Review
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Charbel
      </surname>
      <given-names>
       Khalil
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref> 
     <xref ref-type="aff" rid="aff2"> 
      <sup>2</sup>
     </xref> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Alain
      </surname>
      <given-names>
       Chebly
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff4"> 
      <sup>4</sup>
     </xref> 
     <xref ref-type="aff" rid="aff5"> 
      <sup>5</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Frederic
      </surname>
      <given-names>
       Harb
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff6"> 
      <sup>6</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Fabienne Abi
      </surname>
      <given-names>
       Antoun
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Khalil
      </surname>
      <given-names>
       Akouche
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Rita
      </surname>
      <given-names>
       Khalil
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff7"> 
      <sup>7</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Albert
      </surname>
      <given-names>
       Azar
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff1"> 
      <sup>1</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Maria
      </surname>
      <given-names>
       Khalil
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Bahij
      </surname>
      <given-names>
       Chaar
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff8"> 
      <sup>8</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Samar
      </surname>
      <given-names>
       Abbas
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Colette
      </surname>
      <given-names>
       Hanna
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff3"> 
      <sup>3</sup>
     </xref>
    </contrib>
    <contrib contrib-type="author" xlink:type="simple">
     <name name-style="western">
      <surname>
       Ahmad
      </surname>
      <given-names>
       Ibrahim
      </given-names>
     </name> 
     <xref ref-type="aff" rid="aff6"> 
      <sup>6</sup>
     </xref>
    </contrib>
   </contrib-group> 
   <aff id="aff1">
    <addr-line>
     aReviva Regenerative Medicine Center, Bsalim, Lebanon
    </addr-line> 
   </aff> 
   <aff id="aff2">
    <addr-line>
     aBone Marrow Transplant Unit, Burjeel Medical City, Abu Dhabi, UAE
    </addr-line> 
   </aff> 
   <aff id="aff3">
    <addr-line>
     aSchool of Medicine, Lebanese American University, Beirut, Lebanon
    </addr-line> 
   </aff> 
   <aff id="aff4">
    <addr-line>
     aCenter Jacques Loiselet for Medical Genetics and Genomics (CGGM), Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
    </addr-line> 
   </aff> 
   <aff id="aff5">
    <addr-line>
     aHigher Institute of Public Health, Saint Joseph University, Beirut, Lebanon
    </addr-line> 
   </aff> 
   <aff id="aff6">
    <addr-line>
     aFaculty of Medicine and Medical Sciences, University of Balamand, Tripoli, Lebanon
    </addr-line> 
   </aff> 
   <aff id="aff7">
    <addr-line>
     aAlfardan Medical with Northwestern Medicine, Lusail, Qatar
    </addr-line> 
   </aff> 
   <aff id="aff8">
    <addr-line>
     aFaculty of Medicine and Medical Sciences, American University of Beirut, Beirut, Lebanon
    </addr-line> 
   </aff> 
   <pub-date pub-type="epub">
    <day>
     31
    </day> 
    <month>
     01
    </month>
    <year>
     2024
    </year>
   </pub-date> 
   <volume>
    14
   </volume> 
   <issue>
    01
   </issue>
   <fpage>
    1
   </fpage>
   <lpage>
    19
   </lpage>
   <history>
    <date date-type="received">
     <day>
      2,
     </day>
     <month>
      January
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="published">
     <day>
      28,
     </day>
     <month>
      January
     </month>
     <year>
      2024
     </year> 
    </date> 
    <date date-type="accepted">
     <day>
      28,
     </day>
     <month>
      January
     </month>
     <year>
      2024
     </year> 
    </date>
   </history>
   <permissions>
    <copyright-statement>
     © Copyright 2014 by authors and Scientific Research Publishing Inc. 
    </copyright-statement>
    <copyright-year>
     2014
    </copyright-year>
    <license>
     <license-p>
      This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
     </license-p>
    </license>
   </permissions>
   <abstract>
    Stem cells are the foundation of cellular therapy. They are multipotent cells capable of self-renewing and differentiating into several cell lineages. They are being investigated and used for the treatment of a wide range of diseases. There are various stem cell types and sources, with mesenchymal stem cells standing out as one noteworthy example. With neurological disorders being a major cause of deaths and disabilities worldwide, ongoing studies are investigating the therapeutic potential of mesenchymal stem cells for treating neuropathies. This review comprehensively outlines various neurological diseases and explores the therapeutic potential of mesenchymal stem cells in ischemic stroke, multiple sclerosis, ALS, Alzheimer’s, hypoxia, and glioblastoma. However, there are challenges and limitations in mesenchymal stem cell-based therapies, including concerns about immunocompatibility, maintenance of stemness and differentiation stability, and the potential risk of tumor formation.
   </abstract>
   <kwd-group> 
    <kwd>
     Neurological Disorders
    </kwd> 
    <kwd>
      Mesenchymal Stem Cells
    </kwd> 
    <kwd>
      Exosomes
    </kwd> 
    <kwd>
      Extracellular Vesicles
    </kwd> 
    <kwd>
      Stem Cell Therapy
    </kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <sec id="s1">
   <title>1. Background</title>
   <sec id="s1_1">
    <title>1.1. Neurological Disorders</title>
    <p>Neurological disorders such as multiple sclerosis, Epilepsy and neuromuscular disorders are a wide variety of problems affecting the organization, operation and communication in the nervous system, including both the central nervous system (CNS) and the peripheral nervous system (PNS) <xref ref-type="bibr" rid="scirp.138371-1">
      [1]
     </xref> <xref ref-type="bibr" rid="scirp.138371-2">
      [2]
     </xref> such as seizures and abnormal movements <xref ref-type="bibr" rid="scirp.138371-3">
      [3]
     </xref>. Infections, immune system deregulations, environmental factors, genetic predispositions, or a combination of these factors may cause these disorders <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref>. The quality of life can be significantly affected by neurological illnesses since they frequently cause severe sensory, motor, cognitive, and behavioral deficits <xref ref-type="bibr" rid="scirp.138371-2">
      [2]
     </xref>. Early diagnosis and intervention are crucial for managing symptoms and improving outcomes. The treatment of neurological disorders typically involves a multi-faceted approach, including pharmacological therapies, physical and cognitive rehabilitation, surgical interventions, and lifestyle <xref ref-type="bibr" rid="scirp.138371-5">
      [5]
     </xref> <xref ref-type="bibr" rid="scirp.138371-6">
      [6]
     </xref>. While current treatment options can significantly alleviate symptoms and improve functionality, many neurological disorders, especially neurodegenerative diseases like Alzheimer’s or amyotrophic lateral sclerosis (ALS), still lack definitive cures. Advances in stem cell research hold promise for more effective management in the future.</p>
   </sec>
   <sec id="s1_2">
    <title>1.2. Mesenchymal Stem Cells (MSCs)</title>
    <p>Mesenchymal stromal/stem cells (MSCs) are a subset of adult stem cells that have the capacity to differentiate into various cell types and undergo extensive self-renewal via multiple cell divisions <xref ref-type="bibr" rid="scirp.138371-7">
      [7]
     </xref> <xref ref-type="bibr" rid="scirp.138371-8">
      [8]
     </xref>, and the ability to exert anti-inflammatory and immunosuppressive effects through interactions with a range of immune cells <xref ref-type="bibr" rid="scirp.138371-9">
      [9]
     </xref>, making them a powerful tool in treating different pathologies. MSCs have the capacity to adhere to plastic in cell cultures <xref ref-type="bibr" rid="scirp.138371-10">
      [10]
     </xref>, adopting a fibroblastic morphology that facilitates their expansion and manipulation in vitro <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. Furthermore, MSCs express markers such as CD73, CD90, CD105 <xref ref-type="bibr" rid="scirp.138371-6">
      [6]
     </xref> and they lack the expression of hematopoietic stem cell markers such as CD14, CD34, CD45, and HLA-DR <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. This unique profile aligns with their potential to differentiate along various lineages, including chondrogenic, osteogenic and adipogenic pathways when cultured under appropriate conditions <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. Moreover, MSCs have the ability to express a collection of other markers such as α-actin (indicating their potential to contribute to smooth muscle development <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>, nestin (Tuj-1), and myosin (muscle cell differentiation) <xref ref-type="bibr" rid="scirp.138371-8">
      [8]
     </xref> <xref ref-type="bibr" rid="scirp.138371-9">
      [9]
     </xref>. MSCs also have the potential to express key factors like the transforming growth factor-β (TGF-beta) receptor and integrins, which play pivotal roles in mediating cellular responses to their microenvironment <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref> <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref>. Recent studies highlighted the paracrine effects of MSCs, particularly the bioactive molecules secreted collectively named “Secretome” <xref ref-type="bibr" rid="scirp.138371-13">
      [13]
     </xref>. Secretome is rich in bioactive substances, such as growth factors, cytokines, and microRNA that have been characterized for their neuro-regenerative, neuro-protective, and immunomodulatory attributes <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref> <xref ref-type="bibr" rid="scirp.138371-14">
      [14]
     </xref>. Such properties underpin the rationale for considering MSCs as potential therapeutic agents in the area of neurological disorders, where their mechanisms of action offer potential avenues for ameliorating neurodegenerative processes and fostering neural tissue repair <xref ref-type="bibr" rid="scirp.138371-1">
      [1]
     </xref> <xref ref-type="bibr" rid="scirp.138371-13">
      [13]
     </xref>. The capacity of MSCs to mediate cell repair within the central nervous system (CNS) is essential for the possibility of applying MSC-based therapies in neurological disorders <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref>. This involves the ability of MSCs to migrate toward sites of tissue damage, where they can subsequently differentiate into diverse cell lineages, thereby contributing to tissue regeneration and repair <xref ref-type="bibr" rid="scirp.138371-9">
      [9]
     </xref>. This immunomodulatory role involves the secretion of factors that can both suppress and stimulate immune processes, presenting a finely tuned system that can influence autophagy and affect neuromuscular function <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref>. In the context of neurological disorders, these immunomodulatory attributes may play a pivotal role in mitigating inflammation-driven neuronal damage <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref> <xref ref-type="bibr" rid="scirp.138371-15">
      [15]
     </xref>. The efficacy of MSCs in therapeutic contexts is underscored by their abundant availability, as they can be obtained from diverse sources, including fat, bone marrow, cord blood, muscle tissue, and the placenta <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. The ease of isolation from adipose tissue via lipoaspiration or abdominoplasty has positioned ADMSCs as particularly practical candidates for various therapeutic applications <xref ref-type="bibr" rid="scirp.138371-14">
      [14]
     </xref>. The differentiation processes of MSCs have various distinct pathways that are divided into three types: ectodermal, mesodermal, and endodermal <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. Ectodermal differentiation into the neurogenic line involves the Notch-1 pathway as well as protein kinase A (PKA) pathway. Substances used to induce differentiation include hydrocortisone, dimethyl sulfoxide (DMSO), butylated hydroxyanisole (BHA), and potassium chloride (KCl), as well as basic fibroblast growth factor (bFGF), neurotrophin-3 (NT-3), β-mercaptoethanol (β-ME), brain-derived neurotrophic factors (BDNF), and nerve growth factor (NGF) <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref> <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref>. Meanwhile, differentiation to mesodermal, which includes the osteogenic, chondrogenic, and adipogenic linages, is done through pathways concerning TGF-β, PPAR-γ, Smad3, and SOX9 <xref ref-type="bibr" rid="scirp.138371-11">
      [11]
     </xref>. Osteogenic differentiation is stimulated with dexamethasone (Dex), β-glycerophosphate (β-GP), and ascorbic acid phosphate (aP) <xref ref-type="bibr" rid="scirp.138371-8">
      [8]
     </xref>. Furthermore, alkaline activity and the accumulation of calcium are analyzed to conform the process <xref ref-type="bibr" rid="scirp.138371-8">
      [8]
     </xref>. TGF-β2 and TGF-β1 are used for chondrogenesis, and finally dexamethasone (Dex), 3-isobutyl-1-methylxanthine (IBMX), and indomethacin and methylisobutylxanthine (IM) are used for Adipogenesis <xref ref-type="bibr" rid="scirp.138371-8">
      [8]
     </xref>. Finally, endodermal differentiation is achieved through signaling pathways involving TGF-β, fibroblast growth factor (FGF), and bone morphogenetic protein (BMP). Apart from the secretome, MSCs are recognized for paracrine factors such as exosomes and extracellular vesicles (EVs). EVs are small vesicles <xref ref-type="bibr" rid="scirp.138371-16">
      [16]
     </xref>, containing a phospholipid bilayer that has a wide variety of proteins, DNA, mRNA, and miRNA molecules <xref ref-type="bibr" rid="scirp.138371-17">
      [17]
     </xref>. EVs are released after merging with the plasma membrane of a multivesicular endosome.</p>
    <sec id="s1">
     <title>2. Therapeutic Potential of MSC</title>
     <p>MSC can be used in diabetic pathologies such as: diabetic cardiomyopathy (DCM), diabetic neuropathy (DN), diabetic wounds, diabetic retinopathy (DR), and diabetic foot <xref ref-type="bibr" rid="scirp.138371-13">
       [13]
      </xref>. DCM is caused by extended hyperglycemia resulting in ventricular dysfunction <xref ref-type="bibr" rid="scirp.138371-1">
       [1]
      </xref>; studies showed that MSCs using their growth factors such as vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1) and hepatocyte growth factor (HGF) could promote angiogenesis and myogenesis, thus assisting in regeneration of vascular tissue <xref ref-type="bibr" rid="scirp.138371-18">
       [18]
      </xref> <xref ref-type="bibr" rid="scirp.138371-19">
       [19]
      </xref>. DN is characterized by the excess supply of glucose to the nephron in the kidneys, resulting in angiopathy of capillaries and blood vessels, which supply the glomeruli and release protein into urine <xref ref-type="bibr" rid="scirp.138371-15">
       [15]
      </xref> <xref ref-type="bibr" rid="scirp.138371-20">
       [20]
      </xref>. It is also characterized by neuron damage, decreased sensation, hyperalgesia, and lowered blood supply to the nerves <xref ref-type="bibr" rid="scirp.138371-18">
       [18]
      </xref> <xref ref-type="bibr" rid="scirp.138371-21">
       [21]
      </xref>. Studies have shown that DN MSCs lead to the re-establishment of muscles and blood capillaries by the production of FGF and VEGF <xref ref-type="bibr" rid="scirp.138371-22">
       [22]
      </xref>, improvement in hyperalgesia, and better functioning of nerve fiber while also delaying the nerve conduction velocity <xref ref-type="bibr" rid="scirp.138371-23">
       [23]
      </xref>. In the case of DR, the MSCs promoted regeneration of retinal tissue by differentiating into neurons, photoreceptors, glial cells, and retinal pigment cells <xref ref-type="bibr" rid="scirp.138371-15">
       [15]
      </xref>. In addition, they improved the blood-retinal barrier and photoreceptor cells in the retina. Furthermore, Diabetes mellitus (DM) causes delayed wound healing and tissue necrosis due to a lack of growth factors, angiogenic factors, and unstable collagen matrix formation <xref ref-type="bibr" rid="scirp.138371-15">
       [15]
      </xref> <xref ref-type="bibr" rid="scirp.138371-18">
       [18]
      </xref>. The wound undergoes severe pathogenesis, necrotic tissue entrapment, and reduced function. Transplanting MSCs by circulation improves collagen production, strength, and integrity, leading to wound healing. Salidroside-pretreated MSCs promote paracrine function and neoangiogenesis, reducing hyperglycemia-induced reactive oxygen species generation <xref ref-type="bibr" rid="scirp.138371-7">
       [7]
      </xref> <xref ref-type="bibr" rid="scirp.138371-23">
       [23]
      </xref>. MSCs, with their immunomodulatory and immunosuppressive properties, promote the formation of regulatory T-cells (Treg) and support β-cells survival <xref ref-type="bibr" rid="scirp.138371-12">
       [12]
      </xref>. They release IL-6, which inhibits monocyte differentiation to dendritic cells (DCs) and delay apoptosis. MSCs suppress T-cell proliferation and cytotoxicity <xref ref-type="bibr" rid="scirp.138371-9">
       [9]
      </xref>. Furthermore, CB-MSCs have been reported to restore Th1/Th2 cytokine balance, promote Treg proliferation, and induce apoptosis in pancreatic islets <xref ref-type="bibr" rid="scirp.138371-18">
       [18]
      </xref>. Rheumatoid arthritis (RA) is a chronic autoimmune condition that targets the connective tissues and joints, causing chronic inflammation, pain, stiffness, and loss of mobility <xref ref-type="bibr" rid="scirp.138371-24">
       [24]
      </xref> <xref ref-type="bibr" rid="scirp.138371-25">
       [25]
      </xref>. MSC-based therapy is reported to provide comfort to patients who did not respond to standard-of-care drug-based treatments <xref ref-type="bibr" rid="scirp.138371-21">
       [21]
      </xref>. The collagen-induced arthritis (CIA) model in DBA/1 mice and Brown-Norway rats is an authenticated study for studying disease resolution with drugs and MSCs <xref ref-type="bibr" rid="scirp.138371-26">
       [26]
      </xref> <xref ref-type="bibr" rid="scirp.138371-27">
       [27]
      </xref>. Stem cells injected intravenously or parenterally migrate into inflamed arthritic tissues, reducing pathogenic cytokines and disease severity scores <xref ref-type="bibr" rid="scirp.138371-18">
       [18]
      </xref>. The CIA shares similarities with RA, such as Th1 and Th17 cell involvement and autoantibodies, thus can be considered to represent systemic immune responses in human RA <xref ref-type="bibr" rid="scirp.138371-14">
       [14]
      </xref> <xref ref-type="bibr" rid="scirp.138371-15">
       [15]
      </xref>. As a matter of fact, Augello et al. injected allogeneic bone-marrow MSCs intraperitoneally in DBA/1 mice, showing significant reductions in inflammatory cytokines, Tregs, and disease severity <xref ref-type="bibr" rid="scirp.138371-28">
       [28]
      </xref>. Similarly, Lui et al. reviewed a single intravenous infusion of human umbilical cord MSCs (hUC-MSCs) on CIA in DBA/1 mice. Their research revealed an association between decreased proinflammatory cytokines and alleviation of RA symptoms <xref ref-type="bibr" rid="scirp.138371-29">
       [29]
      </xref>. In another study, Shandil et al. also injected human adipose-derived MSCs (hA-MSCs) intravenously in a mouse model of CIA, causing inhibition of inflammatory mediators and decreased Th1/Th17 cell expansion and induced the production of the anti-inflammatory cytokine IL-10 <xref ref-type="bibr" rid="scirp.138371-4">
       [4]
      </xref> <xref ref-type="bibr" rid="scirp.138371-24">
       [24]
      </xref>. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread tissue inflammation and organ damage <xref ref-type="bibr" rid="scirp.138371-30">
       [30]
      </xref>. MSCs have proved the ability to regulate the immune system and control inflammation by inhibiting the activation of NF-κB, JACK/STAT, and Akt/GSK3β signaling pathways to replenish SLE lesions <xref ref-type="bibr" rid="scirp.138371-14">
       [14]
      </xref>. In fact, MSCs apply immunosuppressive effects through proinflammatory cytokine secretion and inhibition of lymphocyte activation and proliferation <xref ref-type="bibr" rid="scirp.138371-24">
       [24]
      </xref>. SLE is associated with the activation and proliferation of auto reactive B-cells and other T-cells’ subtypes <xref ref-type="bibr" rid="scirp.138371-31">
       [31]
      </xref>. Additionally, the deficiency in anti-inflammatory subsets (Treg, Th2) and proinflammatory subsets (Th17, Th1) represent the crucial elements in SLE’s pathogenesis. These factors lead to tissue inflammation, immune dysfunction and multiorgan failure <xref ref-type="bibr" rid="scirp.138371-24">
       [24]
      </xref> <xref ref-type="bibr" rid="scirp.138371-32">
       [32]
      </xref>. In this context, the most adapted animal model used is the Fas mutated MRL/lpr and NZB/W F1 mice which develop lupus-like symptoms similar to humans and are used to study the mechanism of MSC therapy <xref ref-type="bibr" rid="scirp.138371-33">
       [33]
      </xref>. Jang et al. studied the effect of human bone marrow-derived MSCs (hBM-MSCs) on female NZB/W mice, and found a reduction in autoantibodies, follicular T helper (Tfh) cells, proteinuria and humoral immune components <xref ref-type="bibr" rid="scirp.138371-34">
       [34]
      </xref>. According to a subsequent study by Lee et al., umbilical cord MSCs (hUMSCs) used in the setting of NZB/W F1 mice reduced levels of proinflammatory (TNF-, IL-6, and IL-12) cytokines and inhibited the pathogenic and inflammatory immune response associated with SLE <xref ref-type="bibr" rid="scirp.138371-35">
       [35]
      </xref>. Furthermore, it seemed to postpone the onset of lupus autoimmunity <xref ref-type="bibr" rid="scirp.138371-30">
       [30]
      </xref>. Additionally, a study by Admou et al. showed that levels of the Anti-double-stranded deoxyribonucleic acid antibodies anti-dsDNA antibodies that are specific markers of systemic lupus erythematosus (SLE) <xref ref-type="bibr" rid="scirp.138371-36">
       [36]
      </xref>, the NF-κB signaling pathway, the expression of TNF-alpha, ICAM-1, and plasminogen activator inhibitor-1 (PAI-1), and proteinuria were reduced after xenogeneic transplantation of human placenta-derived MSCs (hP-MSCs) into MRL/lpr mice <xref ref-type="bibr" rid="scirp.138371-24">
       [24]
      </xref>. Similar findings were reported by Zang et al., who found that intravenous injection of hBM-MSC in MRL/lpr mice decreased proteinuria, T-cells proliferation, and serum levels of anti-dsDNA antibodies <xref ref-type="bibr" rid="scirp.138371-21">
       [21]
      </xref>. These investigations concluded that MSCs had an immunoregulatory influence on T-cell populations <xref ref-type="bibr" rid="scirp.138371-21">
       [21]
      </xref>. In addition, Zang et al. showed that injection of allogeneic BM-MSCs to MRL/lpr mice decreased B-cell maturation and differentiation in mice <xref ref-type="bibr" rid="scirp.138371-21">
       [21]
      </xref>.</p>
    </sec>
   </sec>
   <sec id="s3">
    <title>3. Therapeutic Potential of MSC-Derived Exosomes</title>
    <p>MSC-derived exosomes retain the therapeutic effects of MSC. These exosomes bear exosome-associated plasma membranes composed of lipids such as hexosylceramides, cholesterol, phosphatidylserine, sphingomyelin, and saturated fatty acids, coupled with proteins serving diverse roles <xref ref-type="bibr" rid="scirp.138371-7">
      [7]
     </xref> <xref ref-type="bibr" rid="scirp.138371-12">
      [12]
     </xref>. These encompass fusion proteins (e.g. ESCRT complex, ALIX, TSG101, and syntenin), membrane transporter proteins (Rab GTPases and annexins) <xref ref-type="bibr" rid="scirp.138371-35">
      [35]
     </xref>, as well as evolutionarily conserved proteins like tetraspanins (e.g. CD9, CD63, CD81, and CD82), integrins, major histocompatibility complex (MHC) class II proteins, and heat shock proteins, all packaged into exosomes during their formation <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref>. Exosomes play a critical role in cell activity determination. MSC-derived exosomes present MSC-specific markers (CD73, CD44, CD90) and surface markers (CD81, CD9) <xref ref-type="bibr" rid="scirp.138371-7">
      [7]
     </xref> <xref ref-type="bibr" rid="scirp.138371-23">
      [23]
     </xref>. Analysis of BMSC-derived exosomes’ proteomics-based content showcased 730 functional proteins, regulating MSC growth, proliferation, adhesion, migration, and morphogenesis <xref ref-type="bibr" rid="scirp.138371-7">
      [7]
     </xref> <xref ref-type="bibr" rid="scirp.138371-36">
      [36]
     </xref>. These exosomes surpass their parent cells in extracellular-associated proteins. Also, exosomal contents encompass crucial RNA cargoes for immune system regulation, cell differentiation, and survival <xref ref-type="bibr" rid="scirp.138371-37">
      [37]
     </xref>. Prominent miRNAs within these exosomes stimulate angiogenesis, tissue remodeling, and cardiomyocyte increase <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref>. While BMSC and adipose-MSC (AMSC) exosomes share RNA compositions, their tRNA species differ based on MSC differentiation status <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> <xref ref-type="bibr" rid="scirp.138371-20">
      [20]
     </xref>. Significantly, exosomes from both BMSCs and HLSCs carry cellular mRNA that regulates processes such as cell differentiation, transcription, and proliferation. Particularly, exosomes derived from HLSCs express mRNAs that influence metabolism and growth of liver cells <xref ref-type="bibr" rid="scirp.138371-38">
      [38]
     </xref>. Exosomes, encompassing DNA, RNA, and protein species, exhibit several functions. Large dsDNA fragments aid in identifying mutations like KRAS and p53, enabling pancreatic cancer prediction <xref ref-type="bibr" rid="scirp.138371-39">
      [39]
     </xref>. Recipient cells respond to exosomal DNA transfer with diverse biological effects <xref ref-type="bibr" rid="scirp.138371-40">
      [40]
     </xref>. MSC-derived exosomes serve a multitude of functions across various areas as shown in. In terms of tumor growth, they can either stimulate or hinder cancer cell growth by transferring tumor-associated miRNAs. BMSC-derived exosomes are found to target IRF2, inhibiting tumor formation in adult acute myeloid leukemia AML cells which is a type of cancer in where the bone marrow makes a large number of abnormal blood cells <xref ref-type="bibr" rid="scirp.138371-41">
      [41]
     </xref> and additionally, these exosomes carry miR101-3p, inhibiting oral cancer spread by targeting COL10A1, and suppress human lymphoma cells while inducing antioxidant enzyme activities <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> <xref ref-type="bibr" rid="scirp.138371-20">
      [20]
     </xref>. Exosomes from AMSCs induce apoptosis in prostate cancer through miR-145 and inhibit human ovarian cancer through cell cycle arrest and apoptosis <xref ref-type="bibr" rid="scirp.138371-7">
      [7]
     </xref> <xref ref-type="bibr" rid="scirp.138371-42">
      [42]
     </xref>. Exosomes are also implicated in promoting tumor growth, as seen with BMSC-derived exosomes stimulating tumor growth via ERK1/2 signaling in gastric cancer and expediting multiple myeloma development <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref>. Furthermore, exosomes from HUCMSCs exhibit a protective effect and reduce tumor cell apoptosis, suggesting a potential role in chemotherapy protection <xref ref-type="bibr" rid="scirp.138371-43">
      [43]
     </xref>. Exosomes have demonstrated involvement in angiogenesis, promoting tumor growth by enhancing CXCR4 expression and angiogenesis in gastric carcinoma and colon cancer, and influencing Wnt signaling <xref ref-type="bibr" rid="scirp.138371-40">
      [40]
     </xref>. In the context of drug resistance, they play roles in communication during drug treatment, cell migration enhancement, and gene expression induction. Furthermore, these exosomes influence metastasis by affecting dormant cells, stimulating metastatic tumor formation and shuttling miR-205 and miR-31 to suppress metastatic potential, while assisting in tumor migration and dormancy <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> <xref ref-type="bibr" rid="scirp.138371-20">
      [20]
     </xref>. Moreover, exosomes favor invasiveness via purinergic signaling <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref>. They facilitate immune cell subpopulation modulation, including T-cells, NK cells, macrophages, DC, and B-cells interactions <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> <xref ref-type="bibr" rid="scirp.138371-20">
      [20]
     </xref>.</p>
   </sec>
   <sec id="s4">
    <title>4. Therapeutic Potential of EVs</title>
    <p>MSC-derived EVs are considered to be the most promising cell-free therapy for tissue repair and regeneration <xref ref-type="bibr" rid="scirp.138371-44">
      [44]
     </xref> <xref ref-type="bibr" rid="scirp.138371-45">
      [45]
     </xref>. EVs can induce anti-inflammatory, anti-fibrotic, and immunosuppressive effects via miRNA, mRNA, and proteins <xref ref-type="bibr" rid="scirp.138371-46">
      [46]
     </xref>. Research on animals has shown that EV-encapsulated mRNAs, which are involved in transcriptional regulation, proliferation and immune regulation, induced tissue regeneration against acute renal disease <xref ref-type="bibr" rid="scirp.138371-47">
      [47]
     </xref>. Moreover, EVs were used to block the signaling pathway that induced apoptosis and suppressed proliferation of renal epithelial cells in vitro <xref ref-type="bibr" rid="scirp.138371-41">
      [41]
     </xref>. Additionally, in a mouse model of hypoxia-induced pulmonary hypertension, EVs were reported to suppress inflammation, by inhibiting the signal transducer and activator of transcription 3 (STAT3) pathways. Also, these EVs suppressed the upregulation of the hypoxia-inducible miR-17 superfamily and the growth-inhibitory miR-204 <xref ref-type="bibr" rid="scirp.138371-44">
      [44]
     </xref> <xref ref-type="bibr" rid="scirp.138371-48">
      [48]
     </xref>. On the other hand, MSC EVs have been described to have opposing effects such as: tumor progression via tumor microenvironment remodeling and tumor suppression via immune response regulation and intercellular signaling <xref ref-type="bibr" rid="scirp.138371-49">
      [49]
     </xref>. Also, EVs have been deemed safe carriers for antitumor drugs, and they can inhibit the activation and proliferation of a variety of proinflammatory cells such as Th1, Th17, and M1 macrophages <xref ref-type="bibr" rid="scirp.138371-50">
      [50]
     </xref>, leading to reduction in the secretion of proinflammatory cytokines. Simultaneously, they enhance the proliferation of anti-inflammatory cells <xref ref-type="bibr" rid="scirp.138371-51">
      [51]
     </xref>, such as M2 macrophages and Tregs, and they play a role in immune regulation. EVs also exhibit immunomodulatory functions by increasing secretion of proinflammatory cytokines <xref ref-type="bibr" rid="scirp.138371-44">
      [44]
     </xref> <xref ref-type="bibr" rid="scirp.138371-52">
      [52]
     </xref>. Also, EVs show a balance between immune response and immune tolerance, due to the bioactive molecules they carry such as: mRNA, miRNA, cytokines chemokines, immunomodulators, and growth factors <xref ref-type="bibr" rid="scirp.138371-49">
      [49]
     </xref>. MSC-derived EVs control the proliferation and differentiation of T- and B-cells <xref ref-type="bibr" rid="scirp.138371-41">
      [41]
     </xref> <xref ref-type="bibr" rid="scirp.138371-49">
      [49]
     </xref>. When subjected to inflammatory stimulation, EVs carrying activated TGF-β can impede T-cell proliferation <xref ref-type="bibr" rid="scirp.138371-53">
      [53]
     </xref>. This inhibition affects CD4+ T-cells, involving several pathways including Smad. These EVs also harbor HLA-G5, which is capable of suppressing the proliferation of both CD4+ and CD8+ T-cells while decreasing the release of IFN-γ <xref ref-type="bibr" rid="scirp.138371-49">
      [49]
     </xref>. MSC-EVs have been found to down-regulate IL-2 signaling and to inhibit T-cell proliferation by targeting CD25. Also, they promote the differentiation of naive T-cells into anti-inflammatory phenotypes, such as Tregs <xref ref-type="bibr" rid="scirp.138371-49">
      [49]
     </xref>. MSC-EVs mediate Treg differentiation in vitro and in vivo and reduce pathogenic Th17 amplification and proinflammatory factors. Additionally, they increase the number of regulatory B-cells (Bregs) and promote IL-10 secretion <xref ref-type="bibr" rid="scirp.138371-41">
      [41]
     </xref>. Furthermore, MSC-EVs can directly inhibit B-cell proliferation and activation <xref ref-type="bibr" rid="scirp.138371-16">
      [16]
     </xref> <xref ref-type="bibr" rid="scirp.138371-38">
      [38]
     </xref>.</p>
   </sec>
   <sec id="s5">
    <title>5. Use of MSCs in Neurology</title>
    <p>MSCs have emerged as promising remedy for neurological disorders along with ischemic stroke, Alzheimer, hypoxia, and many other brain-related diseases <xref ref-type="bibr" rid="scirp.138371-45">
      [45]
     </xref>. Hypoxia, a condition marked by low oxygen levels within the body tissues, can lead to severe and perilous range of illnesses which include tissue damage and disorders, stroke, coronary heart attack, and breathing failure <xref ref-type="bibr" rid="scirp.138371-54">
      [54]
     </xref>. MSCs have proven efficacy in treating the neurological complications induced by hypoxia. In preclinical studies, MSCs proved to enhance healing in animal models of hypoxia, including stroke and acute breathing misery syndrome <xref ref-type="bibr" rid="scirp.138371-18">
      [18]
     </xref>. Furthermore, different cellular reactions to decreased oxygen stress can be identified during in vitro cultures. This can aid in the proliferation, survival, and migration of MSCs under hypoxic conditions <xref ref-type="bibr" rid="scirp.138371-10">
      [10]
     </xref>. MSCs have reportedly proven potential as a therapeutic alternative for Alzheimer’s disease, a neurodegenerative disorder characterized by means of cognitive decline and reminiscence loss <xref ref-type="bibr" rid="scirp.138371-55">
      [55]
     </xref> by decreasing inflammation, supporting neuronal survival, and enhancing cognitive function <xref ref-type="bibr" rid="scirp.138371-17">
      [17]
     </xref>. These effects can be attributed to the secretion of numerous increase factors and cytokines via MSCs, which could guide neuronal fitness and modulate the immune response <xref ref-type="bibr" rid="scirp.138371-4">
      [4]
     </xref> and promote neuronal survival not only by secreting neuroprotective and anti-inflammatory elements, but also by enhancing microglia clearance of accumulated protein aggregates and moving functional mitochondria and miRNAs to improve the bioenergetic profile of neurons <xref ref-type="bibr" rid="scirp.138371-21">
      [21]
     </xref>. MSC based therapies aim to slow down disease progression via reducing infections and therefore enhancing the quality of life for individuals, especially when detected in early stages <xref ref-type="bibr" rid="scirp.138371-56">
      [56]
     </xref>. MSC can replace damaged or misplaced neuron-like cells. Furthermore, studies have shown that MSCs have the capability to decrease the accumulation of amyloid beta protein, a significant marker of Alzheimer’s disease. As a result, the progression of the disease is delayed, leading to enhanced cognitive abilities <xref ref-type="bibr" rid="scirp.138371-26">
      [26]
     </xref>. Ischemic stroke (IS) is a condition characterized by means of the blockage of blood drift to the brain, resulting in tissue damage and neurological deficits <xref ref-type="bibr" rid="scirp.138371-57">
      [57]
     </xref>. This leads to cell death and cerebral infarction which makes this condition one of the main causes of death and disability <xref ref-type="bibr" rid="scirp.138371-58">
      [58]
     </xref>. The effectiveness of MSC therapy is thought to rely on the homing capacity of MSCs to target lesions and their successful implantation <xref ref-type="bibr" rid="scirp.138371-21">
      [21]
     </xref>. However, the continuous passage of MSCs has been determined to decrease the expression of certain chemokines receptors (consisting of CCR2 and CXCR4), thereby affecting their homing ability. To enhance the homing potential of MSCs <xref ref-type="bibr" rid="scirp.138371-59">
      [59]
     </xref>, it has been discovered that gene modification or pretreatment of MSCs can increase the expression of chemokines (CCR1, CCR2, and CXCR4). This interplay, especially between CCL2/CCR2 and SDF-1/CXCR4, has been shown to seriously enhance the homing and migration of modified MSCs in the course of acute ischemic assault, main to super improvements in neurological <xref ref-type="bibr" rid="scirp.138371-60">
      [60]
     </xref>. Furthermore, in an experimental model of middle cerebral artery occlusion (MCAO), it was reported that only a small fraction of MSCs injected intravenously reached the ischemic brain tissue. Most of these cells were trapped in the lung and spleen, thereby impacting their homing ability <xref ref-type="bibr" rid="scirp.138371-61">
      [61]
     </xref>. On the other hand, another study observed that arterial injection of MSCs facilitated their migration to damaged brain tissue more efficiently <xref ref-type="bibr" rid="scirp.138371-62">
      [62]
     </xref>. Moreover, genetically modified MSCs exhibited prolonged survival in ischemic brain tissue and decreased vascular embolization <xref ref-type="bibr" rid="scirp.138371-63">
      [63]
     </xref>. Exosomes and microvesicles originating from MSCs, being small in size and capable of easily passing through lung tissue, carry various therapeutic molecules that have capacity benefits for stroke remedy <xref ref-type="bibr" rid="scirp.138371-64">
      [64]
     </xref>. However, acquiring enough quantities of extractable exosomes and microvesicles engaged a big variety of MSCs <xref ref-type="bibr" rid="scirp.138371-65">
      [65]
     </xref>. To address this, techniques for culturing MSCs can be enhanced by incorporating microcarriers and whole fiber bioreactors, creating a three-dimensional environment for MSC culture. This allows for substantial amplification of MSCs and facilitating their use in therapy <xref ref-type="bibr" rid="scirp.138371-57">
      [57]
     </xref>. Amyotrophic lateral sclerosis (ALS) is a rare, fatal, idiopathic neurological disease, affecting the neurons responsible for controlling voluntary muscle movements. As for the treatment of ALS, a definitive therapy remains to be discovered <xref ref-type="bibr" rid="scirp.138371-66">
      [66]
     </xref>. Yet, numerous ongoing studies have shown benefits using MSCs based therapy. It was reported that the transplant of MSCs found inside the bone marrow into the spinal canal extensively helped expand the quality of life of ALS patients <xref ref-type="bibr" rid="scirp.138371-59">
      [59]
     </xref>. They secrete neurotrophic elements and rework into useful cells like astrocytes and microglia <xref ref-type="bibr" rid="scirp.138371-67">
      [67]
     </xref>. Cutting-edge remedies for ALS are palliative, but stem cellular therapy offers hope by addressing disease progression through multiple mechanisms <xref ref-type="bibr" rid="scirp.138371-68">
      [68]
     </xref>. The premise is to improve the microenvironment of the disease through transplanting stem cells that generate a neuro-protective milieu, slowing motor neuron degeneration <xref ref-type="bibr" rid="scirp.138371-24">
      [24]
     </xref>. Conversely, glioblastoma (GBM) is a competitive and distinctly invasive and malignant brain tumor that grows rapidly and can severely impact health <xref ref-type="bibr" rid="scirp.138371-69">
      [69]
     </xref>. Studies have revealed that MSCs exhibit anti-tumor characteristics in the setting of GBM. Given that GBM is classified as grade IV within the central nervous system, studies have shown that MSCs potentially possess anti-GBM properties, mainly by regulating angiogenesis, controlling the cell cycle, and inducing apoptosis <xref ref-type="bibr" rid="scirp.138371-69">
      [69]
     </xref>. Moreover, MSCs have been used as sensitizing agents and carriers for delivering specific anti-cancer substances <xref ref-type="bibr" rid="scirp.138371-70">
      [70]
     </xref>. MSCs have confirmed healing ability in various clinical applications, as they are able to either differentiate into specified cell types or release numerous growth and trophic elements to exert their outcomes <xref ref-type="bibr" rid="scirp.138371-71">
      [71]
     </xref>. Although several studies were conducted, and the results indicated very promising outcome, further trials involving a larger population are required to validate the findings and enhance our understanding of the MSC-based therapy <xref ref-type="bibr" rid="scirp.138371-24">
      [24]
     </xref> <xref ref-type="bibr" rid="scirp.138371-25">
      [25]
     </xref>.</p>
   </sec>
   <sec id="s6">
    <title>6. Therapeutic Challenges</title>
    <p>While MSCs show potential and promising results for therapeutic purposes in neurology, and despite several advancements made in the past decade, there are numerous challenges that remain to be addressed for any successful implementation <xref ref-type="bibr" rid="scirp.138371-40">
      [40]
     </xref>. A common misconception among individuals opting for MSC-based therapy is the belief that undergoing this treatment will provide a cure for their condition. However, the treatment will only slow down the advancement of the disease rather than treating it completely <xref ref-type="bibr" rid="scirp.138371-72">
      [72]
     </xref>. A second challenge is to ensure immune compatibility. MSCs may be transplanted as allogeneic cells with a low risk of rejection due to their low expression of MHC-I and HLA-I, and the absence of expression in HLA-II, CD40, CD80 and CD86 <xref ref-type="bibr" rid="scirp.138371-73">
      [73]
     </xref>. Generally, MSCs are believed to have a low immunogenicity, which means they have a reduced potential to trigger an undesirable physiological immune reaction <xref ref-type="bibr" rid="scirp.138371-74">
      [74]
     </xref>. However, it is reported that MSC immunogenicity may increase after extraction from donors due to inappropriate handling methods, environmental factors, and lifestyle conditions <xref ref-type="bibr" rid="scirp.138371-75">
      [75]
     </xref>. Even after injection, the in vivo inflammatory molecules can increase MSCs’ immunogenicity and decrease their viability and differentiation potential. Consequently, an absence of efficacy is seen, leading to the rejection of the injected cells and potentially cause more serious infections. To prevent this, immunocompatibility is the primordial factor to consider <xref ref-type="bibr" rid="scirp.138371-76">
      [76]
     </xref>. Whilst MSCs are recognized for their significant differentiation, regeneration, regulation, and replacement capabilities; various laboratories have demonstrated that genes associated with “stemness” exhibit a high expression rate in both undifferentiated and de-differentiated MSCs <xref ref-type="bibr" rid="scirp.138371-77">
      [77]
     </xref>. Hence, it has been noticed that the differentiation of MSCs into osteoblasts, chondrocytes, adipocytes, and other stemness genes resulted in a decrease in the expression of these genes <xref ref-type="bibr" rid="scirp.138371-23">
      [23]
     </xref>, as indicated in <xref ref-type="table" rid="table1">
      Table 1
     </xref>.</p>
    <table-wrap id="table1">
     <label>
      <xref ref-type="table" rid="table1">
       Table 1
      </xref></label>
     <caption>
      <title>
       <xref ref-type="bibr" rid="scirp.138371-"></xref>Table 1. Table showing different stemness genes of MSCs <xref ref-type="bibr" rid="scirp.138371-78">
        [78]
       </xref>.</title>
     </caption>
     <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
      <tr> 
       <td class="custom-bottom-td acenter" width="19.12%"><p style="text-align:center">Abbreviation</p></td> 
       <td class="custom-bottom-td acenter" width="35.30%"><p style="text-align:center">Names</p></td> 
       <td class="custom-bottom-td acenter" width="45.57%"><p style="text-align:center">Functional Description</p></td> 
      </tr> 
      <tr> 
       <td class="custom-top-td acenter" width="19.12%"><p style="text-align:center">HMGB1</p></td> 
       <td class="custom-top-td acenter" width="35.30%"><p style="text-align:center">High mobility group box 1</p></td> 
       <td class="custom-top-td acenter" width="45.57%"><p style="text-align:center">Interacts with SDF-1 and CXCR4, required for tissue repairment</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">KLF2</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Kruppel-like factor 2</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Enhances MSC proliferation, required for maintenance of stemness</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">MCM2</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Minichromosome maintenance marker 2</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Required for cell division and DNA replication</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">CCNA2</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Cyclin A2</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Regulates cell cycle</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">PCNA</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Proliferating cell nuclear antigen</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Recruits and retains many enzymes required for DNA replication and repairment</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">POLA1</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">DNA polymerase alpha 1</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Required for DNA replication</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">POLD1</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">DNA polymerase delta 1</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Required for DNA replication</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">REC4</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Replication factor C subunit 4</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Required for DNA replication</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">MAD2L1</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Mitotic arrest-deficient 2 like 1</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Executes mitotic checkpoint</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">CDK1</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Cyclin-dependent kinase 1</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">A catalytic subunit of protein kinase complex that induces cell entry into mitosis</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">CCNB1</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Cyclin-B1</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">Predominantly expressed in the G2/M phase of cell division</p></td> 
      </tr> 
      <tr> 
       <td class="acenter" width="19.12%"><p style="text-align:center">CDC45</p></td> 
       <td class="acenter" width="35.30%"><p style="text-align:center">Cell Division cycle 45</p></td> 
       <td class="acenter" width="45.57%"><p style="text-align:center">An important component of the replication for, in DNA unwinding</p></td> 
      </tr> 
     </table>
    </table-wrap>
    <p>Moreover, prolonged culture through serial passaging has the ability to adversely affect the expression of genes related to stemness <xref ref-type="bibr" rid="scirp.138371-79">
      [79]
     </xref>. In an effort to conduct clinical trials with a sufficient quantity of MSCs, it is essential to expand cells’ number on a large scale. However, this method frequently results in the issue of MSC senescence and subsequent adjustments in gene expressions <xref ref-type="bibr" rid="scirp.138371-75">
      [75]
     </xref>. Hence, long-term cultures of MSCs often results in decreased abilities for proliferation and differentiation, as well as a shorter lifespan <xref ref-type="bibr" rid="scirp.138371-80">
      [80]
     </xref>. Although specific molecules have been identified to influence the stemness of MSCs and regulate their differentiation, effectively controlling the fate of MSCs in a complex in vivo environment remains a challenge <xref ref-type="bibr" rid="scirp.138371-81">
      [81]
     </xref>. Another crucial challenge encountered during MSC-based treatment is the potential emergence of cancer-associated MSCs, or tumoral transformation <xref ref-type="bibr" rid="scirp.138371-75">
      [75]
     </xref>. Previous studies revealed that cultured MSCs during their growth display a decrease in the expression of CD13, CD29, CD44, CD73, CD90, CD105, and CD106 compared to MSCs in the stromal fraction. Additionally, the expression of senescence-related proteins such as p53, p21, and p16 varies under different conditions <xref ref-type="bibr" rid="scirp.138371-38">
      [38]
     </xref>. After short-term in vitro cultures, it was observed that wild-type MSCs underwent cellular senescence, whereas p21(-/-) p53(+/+) MSCs exhibited a higher rate of spontaneous apoptosis without any signs of tumoral transformation due to the absence of expression of c-myc protein, associated to this transformation <xref ref-type="bibr" rid="scirp.138371-82">
      [82]
     </xref>. Conversely, different studies have diagnosed cancers-related MSCs (CA-MSCs) characterized by the presence of specific markers CD44, CD73, and CD90 <xref ref-type="bibr" rid="scirp.138371-34">
      [34]
     </xref>. These CA-MSCs exhibited an upregulation of the TGF-β/BMP superfamily and demonstrated the capability to differentiate into cancer-associated fibroblasts (CAFs) during later passages <xref ref-type="bibr" rid="scirp.138371-76">
      [76]
     </xref>. While MSC-based treatment strategies have made significant strides, emerging as the preferred choice for numerous diseases, it is essential to acknowledge the existing challenges.</p>
   </sec>
   <sec id="s7">
    <title>7. Conclusion and Future Perspective</title>
    <p>Due to their immunomodulatory properties, their ability to migrate to damaged tissues, renew and differentiate into multiple cell lineage, MSCs and MSCs-derived exosome therapy holds tremendous promise for the future in addressing neurological diseases. Beyond their regenerative capacities, stem cells and exosomes are subjects of extensive research aiming to elucidate their role in mitigating inflammation. It is significant to investigate these elements for a comprehensive understanding of their therapeutic potential. Research and clinical studies show that MSC-derived exosomes have promising advantages, including reduced immunogenicity and low risk of tumor development. They can also mediate intercellular communication, ultimately resulting in immunomodulation, angiogenesis, neurogenesis, and neuroprotection. In addition, various studies reported the repair of injured peripheral nerves and central nervous system by different MSC-EVs. However, the challenges faced by cell therapies arise from a dearth of theoretical understanding and the absence of uniform guidelines to appraise the therapeutic efficacy of stem cells. The investigation of MSCs-derived extracellular vesicles as a therapeutic approach is garnering increased attention within the scientific community, positioning MSCs as a novel and promising therapy for many diseases, including neurological disorders.</p>
   </sec>
   <sec id="s8">
    <title>Authors’ Contributions</title>
    <p>CK, AC, FH, FAA, KA, RK, AA, MK, BC, SA, CH and AI wrote and edited the manuscript.</p>
   </sec>
   <sec id="s9">
    <title>Funding</title>
    <p>This review received no funding.</p>
   </sec>
   <sec id="s10">
    <title>Data</title>
    <p>Data is available upon request.</p>
   </sec>
   <sec id="s11">
    <title>Abbreviations</title>
    <table class="MsoTableGrid custom-table" border="0" cellspacing="0" cellpadding="0"> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">ALS</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Amyotrophic lateral sclerosis</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">CNS</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Central nervous system</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">PNS</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Peripheral nervous system</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">MSC</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Mesenchymal stem cells</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">ADMSC</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Adipose mesenchymal stem cells</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">PKA</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Protein kinase A</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">DMSO</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Dimethyl sulfoxide</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">BHA</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Butylated hydroxyanisole</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">KCL</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Potassium chloride</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">bFGF</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Basic fibroblast growth factor</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">NT-3</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Neurotrophin-3</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">Β-ME</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">β-mercaptoethanol</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">BDNF</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Brain-derived neurotrophic fac-tors</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">NGF</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Nerve growth factor</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">Dex</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Dexamethasone</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">Β-GP</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">β-glycerophosphate</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">SOX9</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">SRY-box transcription factor 9</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">FGF</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Fibroblast growth factor</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">CD</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Cluster of differentiation</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">HLA</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Human leukocyte antigen</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">EV</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Extracellular vesicle</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">BMMSC</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Bone marrow mesenchymal stem cells</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">TGF-β</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Transforming growth factor β</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">VEGF</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Vascular endothelial growth fac-tor</p></td> 
     </tr> 
     <tr> 
      <td class="aleft" width="18.81%"><p style="text-align:left">JACK/STAT</p></td> 
      <td class="aleft" width="81.19%"><p style="text-align:left">Janus kinase/signal trans-ducers and activators of transcription</p></td> 
     </tr> 
    </table>
   </sec>
  </sec>
 </body><back>
  <ref-list>
   <title>References</title>
   <ref id="scirp.138371-ref1">
    <label>1</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Alessandrini, M., Preynat-Seauve, O., De Briun, K. and Pepper, M.S. (2019) Stem Cell Therapy for Neurological Disorders. South African Medical Journal, 109, 70-77. &gt;https://doi.org/10.7196/samj.2019.v109i8b.14009
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref2">
    <label>2</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Jiang, C., Lin, L., Long, S., Ke, X., Fukunaga, K., Lu, Y., et al. (2022) Signalling Pathways in Autism Spectrum Disorder: Mechanisms and Therapeutic Implications. Signal Transduction and Targeted Therapy, 7, Article No. 229. &gt;https://doi.org/10.1038/s41392-022-01081-0
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref3">
    <label>3</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Steinruecke, M., Mason, I., Keen, M., McWhirter, L., Carson, A.J., Stone, J., et al. (2024) Pain and Functional Neurological Disorder: A Systematic Review and Meta-Analysis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 95, 874-885. &gt;https://doi.org/10.1136/jnnp-2023-332810
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref4">
    <label>4</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Bhagavati, S. (2021) Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical Features, and Therapy. Frontiers in Neurology, 12, Article 664664. &gt;https://doi.org/10.3389/fneur.2021.664664
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref5">
    <label>5</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Bonanni, R., Cariati, I., Tarantino, U., D’Arcangelo, G. and Tancredi, V. (2022) Physical Exercise and Health: A Focus on Its Protective Role in Neurodegenerative Diseases. Journal of Functional Morphology and Kinesiology, 7, Article 38. &gt;https://doi.org/10.3390/jfmk7020038
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref6">
    <label>6</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Simmons, S.B., Skolaris, A., Love, R., Fricker, T., Penko, A.L., Li, Y., et al. (2024) Intensive Aerobic Cycling Is Feasible and Elicits Improvements in Gait Velocity in Individuals with Multiple Sclerosis: A Preliminary Study. International Journal of MS Care, 26, 119-124. &gt;https://doi.org/10.7224/1537-2073.2023-042
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref7">
    <label>7</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Xunian, Z. and Kalluri, R. (2020) Biology and Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes. Cancer Science, 111, 3100-3110. &gt;https://doi.org/10.1111/cas.14563
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref8">
    <label>8</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Babaei, H., Kheirollah, A., Ranjbaran, M., Cheraghzadeh, M., Sarkaki, A. and Adelipour, M. (2023) Preconditioning Adipose-Derived Mesenchymal Stem Cells with Dimethyl Fumarate Promotes Their Therapeutic Efficacy in the Brain Tissues of Rats with Alzheimer’s Disease. Biochemical and Biophysical Research Communications, 672, 120-127. &gt;https://doi.org/10.1016/j.bbrc.2023.06.045
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref9">
    <label>9</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Han, Y., Yang, J., Fang, J., Zhou, Y., Candi, E., Wang, J., et al. (2022) The Secretion Profile of Mesenchymal Stem Cells and Potential Applications in Treating Human Diseases. Signal Transduction and Targeted Therapy, 7, Article No. 92. &gt;https://doi.org/10.1038/s41392-022-00932-0
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref10">
    <label>10</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ohori-Morita, Y., Niibe, K., Limraksasin, P., Nattasit, P., Miao, X., Yamada, M., et al. (2022) Novel Mesenchymal Stem Cell Spheroids with Enhanced Stem Cell Characteristics and Bone Regeneration Ability. Stem Cells Translational Medicine, 11, 434-449. &gt;https://doi.org/10.1093/stcltm/szab030
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref11">
    <label>11</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Kulus, M., Sibiak, R., Stefańska, K., Zdun, M., Wieczorkiewicz, M., Piotrowska-Kempisty, H., et al. (2021) Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials. Cells, 10, Article 3278. &gt;https://doi.org/10.3390/cells10123278
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref12">
    <label>12</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Giovannelli, L., Bari, E., Jommi, C., Tartara, F., Armocida, D., Garbossa, D., et al. (2023) Mesenchymal Stem Cell Secretome and Extracellular Vesicles for Neurodegenerative Diseases: Risk-Benefit Profile and Next Steps for the Market Access. Bioactive Materials, 29, 16-35. &gt;https://doi.org/10.1016/j.bioactmat.2023.06.013
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref13">
    <label>13</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ferreira, J.R., Teixeira, G.Q., Santos, S.G., Barbosa, M.A., Almeida-Porada, G. and Gonçalves, R.M. (2018) Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-Conditioning. Frontiers in Immunology, 9, Article 2837. &gt;https://doi.org/10.3389/fimmu.2018.02837
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref14">
    <label>14</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Laloze, J., Lacoste, M., Marouf, F., Carpentier, G., Vignaud, L., Chaput, B., et al. (2023) Specific Features of Stromal Cells Isolated from the Two Layers of Subcutaneous Adipose Tissue: Roles of Their Secretion on Angiogenesis and Neurogenesis. Journal of Clinical Medicine, 12, Article 4214. &gt;https://doi.org/10.3390/jcm12134214
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref15">
    <label>15</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lamptey, R.N.L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B. and Singh, J. (2022) A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. International Journal of Molecular Sciences, 23, Article 1851. &gt;https://doi.org/10.3390/ijms23031851
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref16">
    <label>16</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Jia, Y., Yu, L., Ma, T., Xu, W., Qian, H., Sun, Y., et al. (2022) Small Extracellular Vesicles Isolation and Separation: Current Techniques, Pending Questions and Clinical Applications. Theranostics, 12, 6548-6575. &gt;https://doi.org/10.7150/thno.74305
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref17">
    <label>17</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Yari, H., Mikhailova, M.V., Mardasi, M., Jafarzadehgharehziaaddin, M., Shahrokh, S., Thangavelu, L., et al. (2022) Emerging Role of Mesenchymal Stromal Cells (MSCs)-Derived Exosome in Neurodegeneration-Associated Conditions: A Groundbreaking Cell-Free Approach. Stem Cell Research &amp; Therapy, 13, Article No. 423. &gt;https://doi.org/10.1186/s13287-022-03122-5
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref18">
    <label>18</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Goenka, V., Borkar, T., Desai, A. and Das, R.K. (2020) Therapeutic Potential of Mesenchymal Stem Cells in Treating Both Types of Diabetes Mellitus and Associated Diseases. Journal of Diabetes &amp; Metabolic Disorders, 19, 1979-1993. &gt;https://doi.org/10.1007/s40200-020-00647-5
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref19">
    <label>19</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Miceli, V., Bulati, M., Iannolo, G., Zito, G., Gallo, A. and Conaldi, P.G. (2021) Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. International Journal of Molecular Sciences, 22, Article 763. &gt;https://doi.org/10.3390/ijms22020763
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref20">
    <label>20</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Yang, J. and Liu, Z. (2022) Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Frontiers in Endocrinology, 13, Article 816400. &gt;https://doi.org/10.3389/fendo.2022.816400
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref21">
    <label>21</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Zang, L., Hao, H., Liu, J., Li, Y., Han, W. and Mu, Y. (2017) Mesenchymal Stem Cell Therapy in Type 2 Diabetes Mellitus. Diabetology &amp; Metabolic Syndrome, 9, Article No. 36. &gt;https://doi.org/10.1186/s13098-017-0233-1
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref22">
    <label>22</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., et al. (2021) Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention. Signal Transduction and Targeted Therapy, 6, Article No. 263. &gt;https://doi.org/10.1038/s41392-021-00658-5
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref23">
    <label>23</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Fuloria, S., Subramaniyan, V., Dahiya, R., Dahiya, S., Sudhakar, K., Kumari, U., et al. (2021) Mesenchymal Stem Cell-Derived Extracellular Vesicles: Regenerative Potential and Challenges. Biology, 10, Article 172. &gt;https://doi.org/10.3390/biology10030172
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref24">
    <label>24</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Shandil, R.K., Dhup, S. and Narayanan, S. (2022) Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases. Stem Cells International, 2022, Article ID: 6379161. &gt;https://doi.org/10.1155/2022/6379161
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref25">
    <label>25</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Bullock, J., Rizvi, S.A.A., Saleh, A.M., Ahmed, S.S., Do, D.P., Ansari, R.A., et al. (2018) Rheumatoid Arthritis: A Brief Overview of the Treatment. Medical Principles and Practice, 27, 501-507. &gt;https://doi.org/10.1159/000493390
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref26">
    <label>26</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Huo, J., Feng, Q., Pan, S., Fu, W., Liu, Z. and Liu, Z. (2023) Diabetic Cardiomyopathy: Early Diagnostic Biomarkers, Pathogenetic Mechanisms, and Therapeutic Interventions. Cell Death Discovery, 9, Article No. 256. &gt;https://doi.org/10.1038/s41420-023-01553-4
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref27">
    <label>27</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Bevaart, L., Vervoordeldonk, M.J. and Tak, P.P. (2009) Collagen-Induced Arthritis in Mice. In: Proetzel, G. and Wiles, M., Eds., Mouse Models for Drug Discovery, Humana Press, 181-192. &gt;https://doi.org/10.1007/978-1-60761-058-8_11
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref28">
    <label>28</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Augello, A., Tasso, R., Negrini, S.M., Cancedda, R. and Pennesi, G. (2007) Cell Therapy Using Allogeneic Bone Marrow Mesenchymal Stem Cells Prevents Tissue Damage in Collagen-Induced Arthritis. Arthritis &amp; Rheumatism, 56, 1175-1186. &gt;https://doi.org/10.1002/art.22511
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref29">
    <label>29</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Liu, Y., Mu, R., Wang, S., Long, L., Liu, X., Li, R., et al. (2010) Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis. Arthritis Research &amp; Therapy, 12, Article No. R210. &gt;https://doi.org/10.1186/ar3187
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref30">
    <label>30</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     García-Carrasco, M., Mendoza Pinto, C., Solís Poblano, J.C., et al. (2013) Systemic Lupus Erythematosus. In: Anaya, J.M., Shoenfeld, Y., Rojas-Villarraga, A., et al., Eds., Autoimmunity: From Bench to Bedside, El Rosario University Press, 12. &gt;https://www.ncbi.nlm.nih.gov/books/NBK459474/ 
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref31">
    <label>31</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Kang, N., Liu, X., You, X., Sun, W., Haneef, K., Sun, X., et al. (2022) Aberrant B-Cell Activation in Systemic Lupus Erythematosus. Kidney Diseases, 8, 437-445. &gt;https://doi.org/10.1159/000527213
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref32">
    <label>32</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Salari, V., Mengoni, F., Del Gallo, F., Bertini, G. and Fabene, P.F. (2020) The Anti-Inflammatory Properties of Mesenchymal Stem Cells in Epilepsy: Possible Treatments and Future Perspectives. International Journal of Molecular Sciences, 21, Article 9683. &gt;https://doi.org/10.3390/ijms21249683
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref33">
    <label>33</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Peutz-Kootstra, C.J., de Heer, E., Hoedemaeker, P.J., Abrass, C.K. and Bruijn, J.A. (2001) Lupus Nephritis: Lessons from Experimental Animal Models. Journal of Laboratory and Clinical Medicine, 137, 244-260. &gt;https://doi.org/10.1067/mlc.2001.113755
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref34">
    <label>34</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Jang, E., Jeong, M., Kim, S., Jang, K., Kang, B., Lee, D.Y., et al. (2016) Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplantation, 25, 1-15. &gt;https://doi.org/10.3727/096368915x688173
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref35">
    <label>35</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lee, J.C., Cha, C.I., Kim, D. and Choe, S.Y. (2015) Therapeutic Effects of Umbilical Cord Blood Derived Mesenchymal Stem Cell-Conditioned Medium on Pulmonary Arterial Hypertension in Rats. Journal of Pathology and Translational Medicine, 49, 472-480. &gt;https://doi.org/10.4132/jptm.2015.09.11
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref36">
    <label>36</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Admou, B., Eddehbi, F., Elmoumou, L., Elmojadili, S., Salami, A., Oujidi, M., et al. (2022) Anti-double Stranded DNA Antibodies: A Rational Diagnostic Approach in Limited-Resource Settings. Practical Laboratory Medicine, 31, e00285. &gt;https://doi.org/10.1016/j.plabm.2022.e00285
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref37">
    <label>37</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Schwarzenbach, H. and Gahan, P.B. (2021) Exosomes in Immune Regulation. Non-Coding RNA, 7, Article 4. &gt;https://doi.org/10.3390/ncrna7010004
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref38">
    <label>38</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Berebichez-Fridman, R. and Montero-Olvera, P.R. (2018) Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-Art Review. Sultan Qaboos University Medical Journal, 18, e264-e277. &gt;https://doi.org/10.18295/squmj.2018.18.03.002
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref39">
    <label>39</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Kalluri, R. and LeBleu, V.S. (2016) Discovery of Double-Stranded Genomic DNA in Circulating Exosomes. Cold Spring Harbor Symposia on Quantitative Biology, 81, 275-280. &gt;https://doi.org/10.1101/sqb.2016.81.030932
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref40">
    <label>40</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lin, Z., Wu, Y., Xu, Y., Li, G., Li, Z. and Liu, T. (2022) Mesenchymal Stem Cell-Derived Exosomes in Cancer Therapy Resistance: Recent Advances and Therapeutic Potential. Molecular Cancer, 21, Article No. 179. &gt;https://doi.org/10.1186/s12943-022-01650-5
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref41">
    <label>41</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     NCI (2023) Acute Myeloid Leukemia Treatment.&gt;https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq 
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref42">
    <label>42</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lynch, O. and Calvi, L. (2022) Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review. Cells, 11, Article 580. &gt;https://doi.org/10.3390/cells11030580
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref43">
    <label>43</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Szwedowicz, U., Łapińska, Z., Gajewska-Naryniecka, A. and Choromańska, A. (2022) Exosomes and Other Extracellular Vesicles with High Therapeutic Potential: Their Applications in Oncology, Neurology, and Dermatology. Molecules, 27, Article 1303. &gt;https://doi.org/10.3390/molecules27041303
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref44">
    <label>44</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ju, Y., Hu, Y., Yang, P., Xie, X. and Fang, B. (2023) Extracellular Vesicle-Loaded Hydrogels for Tissue Repair and Regeneration. Materials Today Bio, 18, Article ID: 100522. &gt;https://doi.org/10.1016/j.mtbio.2022.100522
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref45">
    <label>45</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Aguiar Koga, B.A., Fernandes, L.A., Fratini, P., Sogayar, M.C. and Carreira, A.C.O. (2023) Role of MSC-Derived Small Extracellular Vesicles in Tissue Repair and Regeneration. Frontiers in Cell and Developmental Biology, 10, Article 1047094. &gt;https://doi.org/10.3389/fcell.2022.1047094
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref46">
    <label>46</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Li, S., Zhang, J., Feng, G., Jiang, L., Chen, Z., Xin, W., et al. (2022) The Emerging Role of Extracellular Vesicles from Mesenchymal Stem Cells and Macrophages in Pulmonary Fibrosis: Insights into Mirna Delivery. Pharmaceuticals, 15, Article 1276. &gt;https://doi.org/10.3390/ph15101276
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref47">
    <label>47</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Matsuzaka, Y. and Yashiro, R. (2022) Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine. International Journal of Molecular Sciences, 23, Article 6480. &gt;https://doi.org/10.3390/ijms23126480
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref48">
    <label>48</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Yang, L., Wan, N., Gong, F., Wang, X., Feng, L. and Liu, G. (2023) Transcription Factors and Potential Therapeutic Targets for Pulmonary Hypertension. Frontiers in Cell and Developmental Biology, 11, Article 1132060. &gt;https://doi.org/10.3389/fcell.2023.1132060
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref49">
    <label>49</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Majood, M., Rawat, S. and Mohanty, S. (2022) Delineating the Role of Extracellular Vesicles in Cancer Metastasis: A Comprehensive Review. Frontiers in Immunology, 13, Article 966661. &gt;https://doi.org/10.3389/fimmu.2022.966661
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref50">
    <label>50</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Li, Q., Cai, S., Li, M., Salma, K.I., Zhou, X., Han, F., et al. (2021) Tumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy. International Journal of Nanomedicine, 16, 5395-5409. &gt;https://doi.org/10.2147/ijn.s313912
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref51">
    <label>51</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Xu, Z., Zeng, S., Gong, Z. and Yan, Y. (2020) Exosome-Based Immunotherapy: A Promising Approach for Cancer Treatment. Molecular Cancer, 19, Article No. 160. &gt;https://doi.org/10.1186/s12943-020-01278-3
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref52">
    <label>52</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Wu, R., Fan, X., Wang, Y., Shen, M., Zheng, Y., Zhao, S., et al. (2022) Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. Frontiers in Immunology, 13, Article 833878. &gt;https://doi.org/10.3389/fimmu.2022.833878
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref53">
    <label>53</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Bonowicz, K., Mikołajczyk, K., Faisal, I., Qamar, M., Steinbrink, K., Kleszczyński, K., et al. (2022) Mechanism of Extracellular Vesicle Secretion Associated with TGF-β-Dependent Inflammatory Response in the Tumor Microenvironment. International Journal of Molecular Sciences, 23, Article 15335. &gt;https://doi.org/10.3390/ijms232315335
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref54">
    <label>54</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Nakane, M. (2020) Biological Effects of the Oxygen Molecule in Critically Ill Patients. Journal of Intensive Care, 8, Article No. 95. &gt;https://doi.org/10.1186/s40560-020-00505-9
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref55">
    <label>55</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Hernández, A.E. and García, E. (2021) Mesenchymal Stem Cell Therapy for Alzheimer’s Disease. Stem Cells International, 2021, Article ID: 7834421. &gt;https://doi.org/10.1155/2021/7834421
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref56">
    <label>56</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Sharma, A., Chakraborty, A. and Jaganathan, B.G. (2021) Review of the Potential of Mesenchymal Stem Cells for the Treatment of Infectious Diseases. World Journal of Stem Cells, 13, 568-593. &gt;https://doi.org/10.4252/wjsc.v13.i6.568
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref57">
    <label>57</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Hui, C., Tadi, P., Khan Suheb, M.Z., et al. (2024) Ischemic Stroke. StatPearls.&gt;https://www.ncbi.nlm.nih.gov/books/NBK499997/ 
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref58">
    <label>58</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     DeSai, C. and Hays Shapshak, A. (2023) Cerebral Ischemia. StatPearls. &gt;http://www.ncbi.nlm.nih.gov/books/NBK560510/ 
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref59">
    <label>59</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Xu, R., Ni, B., Wang, L., Shan, J., Pan, L., He, Y., et al. (2022) CCR2-Overexpressing Mesenchymal Stem Cells Targeting Damaged Liver Enhance Recovery of Acute Liver Failure. Stem Cell Research &amp; Therapy, 13, Article No. 55. &gt;https://doi.org/10.1186/s13287-022-02729-y
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref60">
    <label>60</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Marquez-Curtis, L.A. and Janowska-Wieczorek, A. (2013) Enhancing the Migration Ability of Mesenchymal Stromal Cells by Targeting the SDF-1/CXCR4 Axis. BioMed Research International, 2013, Article ID: 561098. &gt;https://doi.org/10.1155/2013/561098
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref61">
    <label>61</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Namestnikova, D.D., Gubskiy, I.L., Revkova, V.A., Sukhinich, K.K., Melnikov, P.A., Gabashvili, A.N., et al. (2021) Intra-Arterial Stem Cell Transplantation in Experimental Stroke in Rats: Real-Time MR Visualization of Transplanted Cells Starting with Their First Pass through the Brain with Regard to the Therapeutic Action. Frontiers in Neuroscience, 15, Article 641970. &gt;https://doi.org/10.3389/fnins.2021.641970
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref62">
    <label>62</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Musiał-Wysocka, A., Kot, M. and Majka, M. (2019) The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplantation, 28, 801-812. &gt;https://doi.org/10.1177/0963689719837897
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref63">
    <label>63</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Luo, R., Lu, Y., Liu, J., Cheng, J. and Chen, Y. (2019) Enhancement of the Efficacy of Mesenchymal Stem Cells in the Treatment of Ischemic Diseases. Biomedicine&amp;Pharmacotherapy, 109, 2022-2034. &gt;https://doi.org/10.1016/j.biopha.2018.11.068
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref64">
    <label>64</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Correale, J. and Marrodan, M. (2022) Multiple Sclerosis and Obesity: The Role of Adipokines. Frontiers in Immunology, 13, Article 1038393. &gt;https://doi.org/10.3389/fimmu.2022.1038393
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref65">
    <label>65</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Phan, J., Kumar, P., Hao, D., Gao, K., Farmer, D. and Wang, A. (2018) Engineering Mesenchymal Stem Cells to Improve Their Exosome Efficacy and Yield for Cell-Free Therapy. Journal of Extracellular Vesicles, 7, Article ID: 1522236. &gt;https://doi.org/10.1080/20013078.2018.1522236
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref66">
    <label>66</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Morris, J. (2015) Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An Overview. The Neurodiagnostic Journal, 55, 180-194. &gt;https://doi.org/10.1080/21646821.2015.1075181
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref67">
    <label>67</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     El Ouaamari, Y., Van den Bos, J., Willekens, B., Cools, N. and Wens, I. (2023) Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives. International Journal of Molecular Sciences, 24, Article 3866. &gt;https://doi.org/10.3390/ijms24043866
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref68">
    <label>68</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Lin, T., Cheng, K., Wu, L., Lai, W., Ling, T., Kuo, Y., et al. (2022) Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects. Frontiers in Cell and Developmental Biology, 10, Article 851613. &gt;https://doi.org/10.3389/fcell.2022.851613
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref69">
    <label>69</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Nowak, B., Rogujski, P., Janowski, M., Lukomska, B. and Andrzejewska, A. (2021) Mesenchymal Stem Cells in Glioblastoma Therapy and Progression: How One Cell Does It All. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188582. &gt;https://doi.org/10.1016/j.bbcan.2021.188582
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref70">
    <label>70</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Campero-Romero, A.N., Real, F.H., Santana-Martínez, R.A., Molina-Villa, T., Aranda, C., Ríos-Castro, E., et al. (2023) Extracellular Vesicles from Neural Progenitor Cells Promote Functional Recovery after Stroke in Mice with Pharmacological Inhibition of Neurogenesis. Cell Death Discovery, 9, Article No. 272. &gt;https://doi.org/10.1038/s41420-023-01561-4
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref71">
    <label>71</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Fan, X., Zhang, Y., Li, X. and Fu, Q. (2020) Mechanisms Underlying the Protective Effects of Mesenchymal Stem Cell-Based Therapy. Cellular and Molecular Life Sciences, 77, 2771-2794. &gt;https://doi.org/10.1007/s00018-020-03454-6
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref72">
    <label>72</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Frykberg, R.G. and Banks, J. (2015) Challenges in the Treatment of Chronic Wounds. Advances in Wound Care, 4, 560-582. &gt;https://doi.org/10.1089/wound.2015.0635
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref73">
    <label>73</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Galieva, L.R., James, V., Mukhamedshina, Y.O. and Rizvanov, A.A. (2019) Therapeutic Potential of Extracellular Vesicles for the Treatment of Nerve Disorders. Frontiers in Neuroscience, 13, Article 163. &gt;https://doi.org/10.3389/fnins.2019.00163
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref74">
    <label>74</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Berglund, A.K., Fortier, L.A., Antczak, D.F. and Schnabel, L.V. (2017) Immunoprivileged No More: Measuring the Immunogenicity of Allogeneic Adult Mesenchymal Stem Cells. Stem Cell Research &amp; Therapy, 8, Article No. 288. &gt;https://doi.org/10.1186/s13287-017-0742-8
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref75">
    <label>75</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Fernández-Francos, S., Eiro, N., Costa, L.A., Escudero-Cernuda, S., Fernández-Sánchez, M.L. and Vizoso, F.J. (2021) Mesenchymal Stem Cells as a Cornerstone in a Galaxy of Intercellular Signals: Basis for a New Era of Medicine. International Journal of Molecular Sciences, 22, Article 3576. &gt;https://doi.org/10.3390/ijms22073576
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref76">
    <label>76</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Goutman, S.A., Savelieff, M.G., Sakowski, S.A. and Feldman, E.L. (2019) Stem Cell Treatments for Amyotrophic Lateral Sclerosis: A Critical Overview of Early Phase Trials. Expert Opinion on Investigational Drugs, 28, 525-543. &gt;https://doi.org/10.1080/13543784.2019.1627324
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref77">
    <label>77</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Pittenger, M.F., Discher, D.E., Péault, B.M., Phinney, D.G., Hare, J.M. and Caplan, A.I. (2019) Mesenchymal Stem Cell Perspective: Cell Biology to Clinical Progress. NPJ Regenerative Medicine, 4, Article No. 22. &gt;https://doi.org/10.1038/s41536-019-0083-6
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref78">
    <label>78</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., et al. (2021) Challenges and Advances in Clinical Applications of Mesenchymal Stromal Cells. Journal of Hematology &amp; Oncology, 14, Article No. 24. &gt;https://doi.org/10.1186/s13045-021-01037-x
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref79">
    <label>79</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Ng, C.P., Mohamed Sharif, A.R., Heath, D.E., Chow, J.W., Zhang, C.B., Chan-Park, M.B., et al. (2014) Enhanced Ex Vivo Expansion of Adult Mesenchymal Stem Cells by Fetal Mesenchymal Stem Cell ECM. Biomaterials, 35, 4046-4057. &gt;https://doi.org/10.1016/j.biomaterials.2014.01.081
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref80">
    <label>80</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Wang, S., Wang, Z., Su, H., Chen, F., Ma, M., Yu, W., et al. (2021) Effects of Long-Term Culture on the Biological Characteristics and RNA Profiles of Human Bone-Marrow-Derived Mesenchymal Stem Cells. Molecular Therapy—Nucleic Acids, 26, 557-574. &gt;https://doi.org/10.1016/j.omtn.2021.08.013
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref81">
    <label>81</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Montazersaheb, S., Ehsani, A., Fathi, E. and Farahzadi, R. (2022) Cellular and Molecular Mechanisms Involved in Hematopoietic Stem Cell Aging as a Clinical Prospect. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 2713483. &gt;https://doi.org/10.1155/2022/2713483
    </mixed-citation>
   </ref>
   <ref id="scirp.138371-ref82">
    <label>82</label>
    <mixed-citation publication-type="other" xlink:type="simple">
     Rodriguez, R., Rubio, R., Masip, M., Catalina, P., Nieto, A., de la Cueva, T., et al. (2009) Loss of P53 Induces Tumorigenesis in P21-Deficient Mesenchymal Stem Cells. Neoplasia, 11, 397-407. &gt;https://doi.org/10.1593/neo.81620
    </mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>